Breast Cancer
Conditions
Keywords
invasive ductal breast carcinoma, invasive lobular breast carcinoma, ductal breast carcinoma in situ, lobular breast carcinoma in situ, stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer
Brief summary
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This clinical trial is studying blood and tumor tissue samples in women with invasive breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or benign breast disease.
Detailed description
OBJECTIVES: Primary * To establish a specimen bank from peripheral blood specimens collected from women with a full spectrum of breast disease (invasive breast cancer \[IBC\], ductal or lobular carcinoma in situ \[CIS\], or benign breast disease \[BBD\]) with standardized clinical follow up and serial specimen collection for those with IBC. * To determine the ability of quantitative real-time reverse-transcriptase PCR (qRT-PCR) to discriminate between patients with IBC, CIS, and BBD by comparing baseline assay values from pre-biopsy specimens to the histologic diagnosis. * To determine the ability of qRT-PCR to predict treatment response by comparing serial assay values from patients with evaluable IBC to their objective response. * To determine the ability of qRT-PCR to predict relapse by comparing the serial assay values from all patients with IBC to their disease status. * To determine the ability of qRT-PCR to perform as an independent prognostic factor by comparing baseline assay values from all patients with IBC to their disease status, stratified by known breast cancer prognostic factors. Secondary * To perform exploratory studies identifying potential targets for novel nucleic acid and proteomic-based early detection assays. OUTLINE: Patients undergo baseline peripheral blood specimen collection pre-biopsy and then periodically for up to 10 years. Specimens are analyzed for circulating tumor cells via quantitative real-time reverse-transcriptase PCR, immunofluorescence, and bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification; and for protein profiles via mass spectometry, liquid chromatography, enzyme digestion, and tandem mass spectometry. Patients' tumor tissue (invasive breast cancer \[IBC\] only) is analyzed for p53 via IHC. Medical records are reviewed periodically. Patients with IBC complete a quality of life assessment at baseline and every 6 months for up to 10 years.
Interventions
GENETICgene expression analysis
GENETICmutation analysis
GENETICproteomic profiling
GENETICreverse transcriptase-polymerase chain reaction
OTHERimmunohistochemistry staining method
OTHERlaboratory biomarker analysis
OTHERmass spectrometry
OTHERmedical chart review
PROCEDUREquality-of-life assessment
Sponsors
National Cancer Institute (NCI)
City of Hope Medical Center
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Biopsy-confirmed diagnosis of one of the following: * Stage I-IV infiltrating ductal or infiltrating lobular carcinoma * Patients with early-stage disease must not have started systemic treatment; if no systemic treatment is planned, patients must be either preoperative or ≤ 120 days since definitive breast surgery * Patients with locally advanced disease must be scheduled for neoadjuvant chemotherapy prior to initiation of systemic treatment * Ductal carcinoma in situ * Lobular carcinoma in situ * Benign breast disease * Proliferative or non-proliferative * With or without atypia PATIENT CHARACTERISTICS: * Karnofsky performance status 50-100% * Not pregnant * No prior invasive cancer diagnosis within the past 5 years except for squamous cell or basal cell carcinoma of the skin PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior systemic therapy (chemotherapy or hormonal therapy) for patients with stage I-III disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establishment of a specimen bank | 5 Years of specimen collection |
| Ability of the quantitative real-time reverse-transcriptase PCR (qRT-PCR) to distinguish between biopsy benign and malignant results | 5 years |
| Ability of the qRT-PCR to predict treatment response | 5 years |
| Ability of the qRT-PCR to predict relapse | 5 years |
| Ability of the qRT-PCR to perform as an independent prognostic factor | 5 years |
Countries
United States
Outcome results
None listed